Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Change in Acquisitions & Divestments: 2016-2024

Historic Change in Acquisitions & Divestments for Protagonist Therapeutics (PTGX) over the last 9 years, with Dec 2024 value amounting to $323.6 million.

  • Protagonist Therapeutics' Change in Acquisitions & Divestments rose 74.78% to $102.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $444.6 million, marking a year-over-year increase of 74.85%. This contributed to the annual value of $323.6 million for FY2024, which is 112.32% up from last year.
  • Per Protagonist Therapeutics' latest filing, its Change in Acquisitions & Divestments stood at $323.6 million for FY2024, which was up 112.32% from $152.4 million recorded in FY2023.
  • Protagonist Therapeutics' Change in Acquisitions & Divestments' 5-year high stood at $323.6 million during FY2024, with a 5-year trough of $152.4 million in FY2023.
  • For the 3-year period, Protagonist Therapeutics' Change in Acquisitions & Divestments averaged around $261.0 million, with its median value being $307.1 million (2022).
  • Its Change in Acquisitions & Divestments has fluctuated over the past 5 years, first plummeted by 50.38% in 2023, then spiked by 112.32% in 2024.
  • Protagonist Therapeutics' Change in Acquisitions & Divestments (Yearly) stood at $189.5 million in 2020, then surged by 43.42% to $271.8 million in 2021, then rose by 12.99% to $307.1 million in 2022, then slumped by 50.38% to $152.4 million in 2023, then soared by 112.32% to $323.6 million in 2024.